medicine

Athenex, Cancer Research UK and NIHR to trial innovative oral chemotherapy

Date: 10 January 2019 to 31 December 2019

An experimental chemotherapy drug that can be taken orally is moving into early phase clinical trials as part of a new partnership between Athenex, Cancer Research UK’s Combinations Alliance and the NIHR Clinical Research Network Industry Alliance.

This unique industry-academic initiative will be run through the Experimental Cancer Medicine Centres and the NIHR Clinical Research Network.

Professor Matt Seymour, NIHR Clinical Research Network, Specialty Cluster Lead said:
"This is a good example of the UK’s unique environment for bringing together academic researchers, industry innovators and the NHS, to join forces and design clinical research trials for more of our patients. I welcome this new alliance. Most anticancer drugs need to be given by injection in hospital, but programmes like this allowing effective drugs to be taken in tablet form at home, could potentially improve our patients’ experience, and may open up opportunities for more sustained treatment, to keep cancers under better control."

Read the full story on the Cancer Research UK website

  • Summary:
    An experimental chemotherapy drug that can be taken orally is moving into early phase clinical trials.
  • Include on homepage (one at a time):
    Yes
  • Areas of the site this news is applicable to:
    • Industry
    • Research
  • LCRN:
  • Year of publication:
    2019
  • Specialty:
    Cancer
  • News filter:
    • Life Sciences Industry
    • News
    • Partnering with us


You may also be interested in